Global HealthPharmaceutical Regulations in Japan

Cooperation with Stakeholders

JPMA worked or is working on following activities engaging with diverse stakeholders.

Joint Statement (July 2012)

JPMA published a joint statement on internet sales and access to safe medicines with the other major pharmaceutical industry associations, IFPMA, PhRMA and EFPIA. The associated material is available externally via the following links.

Furthermore, the IFPMA, in cooperation with the Fondation Chirac, International Council of Nurses (ICN), International Institute of Research Against Counterfeit Medicines (IRACM), Medicines for Malaria Venture (MMV), NCD Alliance, U.S. Pharmacopeial Convention (USP), World Medical Association (WMA), and the World Heart Federation, is conducting the “Fight the Fakes” campaign, and the JPMA is also supporting this initiative.

Anti-Counterfeit Seminar

JPMA convenes anti-counterfeit seminars inviting anti-counterfeit specialist in order to share intelligence of domestic and foreign cases of counterfeit medicines. On 24 October 2017, JPMA held “Anti-Counterfeit Seminar 2017”. 21 JPMA member companies and approximately 60 participants attended the seminar. In this seminar, under the incident of counterfeit case of Harvoni® occurred in Japan in 2017, JPMA invited experts from the Ministry of Health, Labor and Welfare, Compliance and Narcotics Division, Gilead Sciences, Pharmaceutical Security Institute (PSI), LegitScript and Eisai to discuss the actual conditions of counterfeit medicines in Japan and abroad and the current state of countermeasures.

Collaboration with PSI (Pharmaceutical Security Institute)

Thirty-three global pharmaceutical companies have given funding to PSI its efforts to combat counterfeit medicines (including gathering information, collaboration with law-enforcement and raising awareness). JPMA member companies such as Astellas, Chugai, Dainippon Sumitomo, Eisai, Otsuka, and Takeda participated in this initiative.

Collaboration with INTERPOL

From 2013 to 2015, Twenty-nine global pharmaceutical companies gave funding to INTERPOL for its efforts to combat counterfeit medicines (including raising awareness, exposing counterfeiters and distributors, capacity building for discovery of counterfeit medicines). JPMA member companies such as Astellas, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Otsuka, Shionogi and Takeda participated in this initiative.

Page Top

  • Office of Pharmaceutical Industry Research(OPIR)
  • Global Health
  • Stop AMR
  • APAC